Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryAs the biotech job market shows signs of warming, the real effects on various stakeholders—employees, leadership, and prospective job seekers—are nuanced and multifaceted. Executive coach Angela Justice provides insight into these dynamics, highlighting what this shift means for each group.
Dr. Priya NandakumarMar 4, 2026
Healthcare InvestmentThe recent Series D funding round for Grow Therapy underscores a growing industry focus on scalable mental health solutions integrated with employer and health system networks. This capital infusion aims to broaden Grow Therapy's footprint in connecting patients to necessary mental health care resources, thereby addressing increasing demand.
Dr. Priya NandakumarMar 4, 2026
Biopharmaceutical IndustryThe partnership between Boehringer Ingelheim and OSE Immunotherapeutics on the MASH program has come to an end due to underwhelming clinical outcomes in mid-stage trials. As a result, OSE is strategically realigning to concentrate on advancing its lead candidate lusvertikimab, targeting ulcerative colitis, while deprioritizing other assets such as OSE-230 partnered with AbbVie.
Dr. Priya NandakumarMar 3, 2026
Healthcare InvestmentIn the rapidly evolving healthcare AI sector, investors are shifting their focus towards tangible returns amid heightened market scrutiny. This post explores the insights from four prominent venture capitalists on what matters most for AI startups to succeed in today's environment.
Dr. Priya NandakumarMar 3, 2026
Regulatory & PolicyThis month, stakeholders in the pharmaceutical and medical communities are focusing on the Food and Drug Administration's (FDA) pending decisions, which were delayed from 2025. These delays affect potential therapies addressing a rare form of obesity and dry eye disease, signaling complexities involved in regulatory evaluations for these conditions.
Dr. Priya NandakumarMar 2, 2026
Biotech InnovationEmerging from the legacy of Avidity Biosciences and supported by a substantial investment, Atrium Therapeutics is a new biotech company dedicated to developing RNA therapies for rare cardiac conditions. Their pipeline shines a light on a critical area with unmet medical needs, aiming to transform treatment options where none currently exist.
Dr. Priya NandakumarMar 1, 2026
Biopharmaceutical IndustryDuring a period of tight biotech capital markets, LB Pharma successfully completed one of the year’s most successful initial public offerings. This achievement highlights the resilience and strategic foresight of CEO Heather Turner and her team as they advanced a promising schizophrenia drug candidate.
Dr. Priya NandakumarFeb 25, 2026
Regulatory & PolicyThe management of rare diseases necessitates a nuanced regulatory approach that balances the urgency of patient access with the imperative of safety. Sarepta Therapeutics' experience with its drug Elevidys illustrates the challenges and lessons for regulatory frameworks.
Dr. Priya NandakumarFeb 25, 2026
Biotech InnovationThe funding round marks a significant milestone for Slate Medicines as it prepares its Phase 1-ready antibody drug designed to block PACAP, aiming to address the substantial unmet need in migraine therapy. The asset was licensed from DartsBio Pharmaceuticals, reflecting international collaboration in biotech innovation.
Dr. Priya NandakumarFeb 24, 2026
Biotech InnovationThe preclinical Alzheimer’s drug relies on Korsana’s proprietary platform technology that enables antibodies to traverse the blood-brain barrier. This advancement parallels approaches by Roche and AbbVie, reflecting a significant leap in the therapeutic landscape against Alzheimer's disease.
Dr. Priya NandakumarFeb 22, 2026
Medical TechnologyMercyhealth’s integration of Arintra’s AI-powered medical coding solution has notably improved financial performance by streamlining coding automation, identifying documentation gaps, and customizing claims to specific payers, underscoring the transformative potential of AI in healthcare revenue cycles.
Dr. Priya NandakumarFeb 21, 2026
Healthcare InvestmentPitchBook's analysis reveals that $33.8 billion was invested in biopharma during 2025, predominantly directed to companies with advanced stage programs close to clinical implementation. Early-stage firms are facing significant hurdles in securing venture funding amid rising concerns over risk and regulatory uncertainty.
Dr. Priya NandakumarFeb 18, 2026